CompletedNCT04127058
Iloperidone Dose Schedule for Bipolarity or Schizophrenia
About this title
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
Read the official source — NCT04127058Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- MarltonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: October 7, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04127058
- Official title
Show the full official title
A Safety/Tolerance Study to Evaluate a New Titration Scheme in Patients With Bipolar I Disorder or Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Marlton
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Iloperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
